Azetidine and cyclobutane derivatives as jak inhibitors

Abstract

The present invention relates to azetidine and cyclobutane derivatives, as well as their compositions, methods of use, and processes for preparation, which are JAK inhibitors useful in the treatment of JAK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.

1 - 130 . (canceled) 
     
     
         131 . {1-(cyclopropylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharmaceutically acceptable salt thereof. 
     
     
         132 . {1-(propylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharmaceutically acceptable salt thereof. 
     
     
         133 . {1-[(1-methyl-1H-pyrazol-3-yl)sulfonyl]-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharmaceutically acceptable salt thereof. 
     
     
         134 . 3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]cyclobutanecarbonitrile, or a pharmaceutically acceptable salt thereof. 
     
     
         135 . {1-(ethylsulfonyl)-3-[3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrrol-1-yl]azetidin-3-yl}acetonitrile, or a pharmaceutically acceptable salt thereof. 
     
     
         136 . A composition comprising a compound of  claim 131 , or pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier. 
     
     
         137 . A method of treating an autoimmune disease in a patient in need thereof, comprising administering to said patient an effective amount of a compound of  claim 131 , or pharmaceutically acceptable salt thereof. 
     
     
         138 . A method of treating an inflammatory disease in a patient in need thereof, comprising administering to said patient an effective amount of a compound of  claim 131 , or pharmaceutically acceptable salt thereof. 
     
     
         139 . A composition comprising a compound of  claim 132 , or pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier. 
     
     
         140 . A method of treating an autoimmune disease in a patient in need thereof, comprising administering to said patient an effective amount of a compound of  claim 132 , or pharmaceutically acceptable salt thereof. 
     
     
         141 . A method of treating an inflammatory disease in a patient in need thereof, comprising administering to said patient an effective amount of a compound of  claim 132 , or pharmaceutically acceptable salt thereof. 
     
     
         142 . A composition comprising a compound of  claim 133 , or pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier. 
     
     
         143 . A method of treating an autoimmune disease in a patient in need thereof, comprising administering to said patient an effective amount of a compound of  claim 133 , or pharmaceutically acceptable salt thereof. 
     
     
         144 . A method of treating an inflammatory disease in a patient in need thereof, comprising administering to said patient an effective amount of a compound of  claim 133 , or pharmaceutically acceptable salt thereof. 
     
     
         145 . A composition comprising a compound of  claim 134 , or pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier. 
     
     
         146 . A method of treating an autoimmune disease in a patient in need thereof, comprising administering to said patient an effective amount of a compound of  claim 134 , or pharmaceutically acceptable salt thereof. 
     
     
         147 . A method of treating an inflammatory disease in a patient in need thereof, comprising administering to said patient an effective amount of a compound of  claim 134 , or pharmaceutically acceptable salt thereof. 
     
     
         148 . A composition comprising a compound of  claim 135 , or pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier. 
     
     
         149 . A method of treating an autoimmune disease in a patient in need thereof, comprising administering to said patient an effective amount of a compound of  claim 135 , or pharmaceutically acceptable salt thereof. 
     
     
         150 . A method of treating an inflammatory disease in a patient in need thereof, comprising administering to said patient an effective amount of a compound of  claim 135 , or pharmaceutically acceptable salt thereof.